loader2
Partner With Us NRI

Company details

88.00
92.40
71.00
160.80
6M Return -13.17%
1Y Return -43.30%
Mkt Cap.(Cr) 750.44
Volume 3,804
Div Yield 0.34%
OI
-
OI Chg %
-
Volume 3,804

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Rapid Results

Q2FY22 Quarterly Result Announced for SMS Pharmaceuticals Ltd.

Highlights:

  • Revenue grew by 34% YoY
  • EBITDA Margin expanded by 867bps to 27.6%, driven by improved product mix and realisations
  • Profit after tax (PAT) grew by 123% YoY

Commenting on the results Mr. P. Vamsi Krishna, Executive Director - SMS Pharmaceuticals Limited said, "The company continued to maintain the robust growth trajectory. For Q2FY22, thecompany registered revenue, EBITDA and PAT growth of 34%, 96% and 123%, respectively, on YoY basis. EBITDA margins expanded approximately by 870bps. The robust performance was driven by improved product mix, pick-up in the key therapeutic areas and the operating leverage. This performance a testimony of company's agility, adaptability and strong execution capabilities. The growth trajectory is expected to accelerate in the upcoming quarters underpinned by company's leadership position in top therapeutic areas, strong demand, healthy product launch pipeline.

SMS Pharma, as a strategy, has focused on quality, market leadership and backward integration steered by strong R&D capabilities, in top therapeutic areas such as ARV, anti-migraine and anti ulcer over the years. This strategy has boded well, as the company did not witness any impact by recent supply chain disruptions and higher input costs. It has also reduced the import dependency on China significantly for KSMS and key raw materials.

Company's global presence, strong domain expertise, cost leadership, economies of scale and long standing relationships with suppliers and customers has created a unique value proposition. As a result, SMS Pharma has emerged as sustainable, scalable and self-reliant API player. Going forward, the company will continue to invest in backward integration to further strengthen the value proposition. The company is also leveraging long-standing relationships and domain expertise to foray into new therapies, products and geographies.

The company has incurred a capex of Rs. 198 crores in FY21 aimed towards capacity augmentation at the Vizag plant. This brownfield capex is aimed towards capacity augmentation multiple products and therapies. The incremental capacity addition through the capex is 1,300 KL, predominantly aimed towards Ibuprofen capacity expansion. With this capex, company is expected to be one of the largest Ibuprofen manufacturers globally. Majority of the capex is funded through internal accruals and minimal debt, thus maintaining the robust Balance Sheet position. Higher margins and profitability ratios expected through operating leverage and incremental revenue. This capacity augmentation is expected to commercialize fully by the end of FY22.

Multiple industry tailwinds such as favourable geo-political conditions, Make in India, PLI Scheme, China 1 strategy, cost structure coupled with internal triggers such as capacity expansion, leadership position in key therapies and strong balance sheet are expected to drive the next leg of growth along with improved margins and return ratios."

 

 

Result PDF

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 470.29 Cr FV: 1.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 15,509.20 -8,578.65
LAST 3M 18,287.41 29,096.76
LAST 6M 90,792.99 -64,390.79
LAST 12M 213,883.43 -208,257.14

Information

  • About Company
  • Company Info
  • Listing Info
29.67
64.17%
55.5555
12.5%
15.41%
Description
  • SMS Pharmaceuticals Limited is a Public company incorporated in December 14, 1987. The company is engaged in the business of manufacturing of Active Pharma Ingredients and their intermediates. Apart from R &D Center at Gagillapur, Hyderabad, the company is having manufacturing facilities at Bachupally, Hyderabad and also at Kandivalasa in Vijayanagaram Dist. Its business activity is a single primary business segment of `Bulk Drugs`. During the year 2015, the company has re-enforced its fundamental strength of FDA compliant facilities by successfully completing the US FDA audits at Kandivalasa and Bachupally facilities. During the year 2015, the company filed 9 Drug Master Files and total DMFs filed up to 31 March 2015 are 24. During the year 2014-15, the Company acquired 12,25,900 equity shares of Rs. 10/- each in M/s. VKT Pharma Private Limited. With this the said company has become an associate company. The project of the said associate company is in final stage and at the verge of completion and operations are yet to be commenced. The Company has not having any subsidiaries. During the year 2015-16, the Company had sub divided the face value of share of Rs 10/- each into face value of Rs 1/- of each with record date of 18th December 2015. During FY 2015-16, the Board has approved the `Draft Scheme of Arrangement for Demerger of Semi Regulated Units (Unit - I, IV & V) along with other Assets to transfer the same to SMS Lifesciences India Limited (Resulting Company), with an object to reduce the impact of Semi Regulated Units on Regulated Units, achieving operational efficiencies, site synergies and streamlining its current structure. The Draft Scheme of Arrangement is subject to the Approvals of Stock Exchanges, Securities Board of India Limited, Reserve Bank of India and other regulatory authorities and also Hon`ble High Court of Judicature at Hyderabad for the State of Telangana and Andhra Pradesh. During FY 2016-17, the Company had made investment in it`s associate Company viz. M/s. VKT Pharma Private Limited for its business purpose. During the year under review 2016-17, the Company had acquired 5,11,400 equity shares of face value of Rs 10/- each in the said associate at an average price of Rs 157.21. Further, the Company had also made an investment in 1000 equity shares of Sireen Drugs Private Limited of Rs 10/- each. SMS Lifesciences India Limited is the wholly owned subsidiary of the Company during the Financial Year 2016-17. In FY 2017-18, the Scheme of arrangement between SMS Pharmaceuticals Limited (Demerged Company) with SMS Lifesciences India Limited (Resulting Company) and their respective Shareholders and Creditors provides for the demerger of the Semi Regulated Units No. I, IV and V along with premises situated at Industrial Estate, Santhnagar, Hyderabad; Industrial Development Area, Jeedimetla, Hyderabad ; Premises bearing Flat No.417, Nilgiri, Aditya Enclave, Ameerpet, Hyderabad; vacant land admeasuring Ac 19 cents situated at Pharma City, Parawada, Visakhapatnam and Investments relating to Semi Regulated Units (Demerged Undertaking) of SMS Pharmaceuticals Limited, the `Demerged Company` into SMS Lifesciences India Limited, the `Resulting Company as specified in the scheme. The scheme was approved by the Hon`ble National Company Law Tribunal, Hyderabad Bench vide its Order No. C.P (CAA) No.7/230/232/HDB/2017 dated 15th May 2017. The effective date of the Scheme is 17th May 2017. SMS Lifesciences India Limited (Resulting Company) in accordance with the approved Scheme of Arrangement has allotted 30,23,287 equity shares of Rs.10/- each to the shareholders of the company by fixing Record Date as on 23rd June, 2017. Pursuant to approved Scheme, the Resulting Company shares will be listed on Stock Exchanges viz., BSE & NSE where the equity shares of SMS Pharmaceuticals Limited are listed. The Company had made investment in its associate company viz. M/s. VKT Pharma Private Limited for its business purpose. During the year under review 2017-18, the Company had acquired 7,84,100 equity shares of face value of Rs.10/- each in the said associate at an average price of Rs.200.81. During FY 2018-19, the Company had made investment in it`s associate Company viz. M/s. VKT Pharma Private Limited for its business purpose. The Company held 38,50,165 equity shares of Rs 10/- each in VKT Pharma Private Limited as on 31st March 2019 as investments.

Read More

Registered Address

19 III Rd 71 Opp Bharatividya, Bhavan Public Sch Jubilee Hill, Hyderabad, Telangana, 500096

Tel : 91-40-66288888
Email : info:smspharma.com
Website : http://www.smspharma.com

Registrar

Aarthi Consultants Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 532815
NSE Code : SMSPHARMA
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE812G01025

ICICIdirect SMS Pharmaceuticals Ltd FAQ

You can buy SMS Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy SMS Pharmaceuticals Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Oct 06, 2022 04:01 PM the closing price of SMS Pharmaceuticals Ltd was ₹ 88.65.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Oct 06, 2022 04:01 PM, the market cap of SMS Pharmaceuticals Ltd stood at ₹ 750.44.
The latest PE ratio of SMS Pharmaceuticals Ltd as of Oct 06, 2022 04:01 PM is 29.67
The latest PB ratio of SMS Pharmaceuticals Ltd as of Oct 06, 2022 04:01 PM is 0.62
The 52-week high of SMS Pharmaceuticals Ltd is ₹ 160.80 while the 52-week low is ₹ 71.00 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE